A Phase IIa, Multicenter, Placebo- and Active-controlled, Randomized, Double-Blind, Clinical Trial to Evaluate the Safety and Efficacy of MK-8521 Compared to Placebo in Subjects With Type 2 Diabetes Mellitus
Phase of Trial: Phase II
Latest Information Update: 14 Jun 2017
At a glance
- Drugs MK 8521 (Primary) ; Liraglutide
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 10 Jun 2017 Biomarkers information updated
- 19 Apr 2017 Status changed from active, no longer recruiting to completed.
- 04 Apr 2017 Planned End Date changed from 14 Jul 2017 to 11 Apr 2017.